➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Mallinckrodt
McKesson
Moodys
Merck

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

OMNARIS Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Omnaris, and when can generic versions of Omnaris launch?

Omnaris is a drug marketed by Covis and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seven patent family members in thirty-six countries.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.

US ANDA Litigation and Generic Entry Outlook for Omnaris

Omnaris was eligible for patent challenges on October 20, 2010.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for OMNARIS
International Patents:107
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 46
Clinical Trials: 7
Patent Applications: 3,906
Formulation / Manufacturing:see details
Drug Prices: Drug price information for OMNARIS
What excipients (inactive ingredients) are in OMNARIS?OMNARIS excipients list
DailyMed Link:OMNARIS at DailyMed
Drug patent expirations by year for OMNARIS
Drug Prices for OMNARIS

See drug prices for OMNARIS

Recent Clinical Trials for OMNARIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TakedaPhase 3
SunovionPhase 4
West Penn Allegheny Health SystemPhase 4

See all OMNARIS clinical trials

Paragraph IV (Patent) Challenges for OMNARIS
Tradename Dosage Ingredient NDA Submissiondate
OMNARIS SPRAY, METERED;NASAL ciclesonide 022004 2012-02-13

US Patents and Regulatory Information for OMNARIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes   Start Trial   Start Trial   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMNARIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006   Start Trial   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006   Start Trial   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006   Start Trial   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006   Start Trial   Start Trial
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKesson
McKinsey
Moodys
Dow